Understanding Gastroparesis Symptoms and Diagnosis with Ozempic Use

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Legal Concerns

If you or someone you know is taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, it may be more than a passing side effect. Gastroparesis, a condition where the stomach empties too slowly, has been increasingly reported with this medication. Building on decades of research into drug-induced gastrointestinal disorders, this page clarifies the difference between common symptoms and a formal gastroparesis diagnosis, and what steps to consider next.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, where retention of a solid meal is measured at intervals; abnormal retention at 4 hours is a common diagnostic criterion. The condition can significantly impair quality of life and may require dietary modifications, prokinetic medications, or, in severe cases, surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology includes slowing of gastric emptying, which contributes to its glucose-lowering effects by reducing postprandial glucose excursions. However, this mechanism also underlies the gastrointestinal adverse reactions observed in clinical trials. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Risk of Gastroparesis

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's effect on GLP-1 receptors in the gastrointestinal tract, which inhibit gastric motility and slow gastric emptying. While this effect is intended for glycemic control, it can become pathological in susceptible individuals, leading to symptomatic gastroparesis. Postmarketing reports have highlighted a related risk: there have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for clinically significant delayed gastric emptying. The adequacy of warnings regarding Ozempic and gastroparesis is a central risk anchor. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and the risk of pulmonary aspiration, but it does not explicitly list gastroparesis as a specific adverse reaction. The label notes that available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Ozempic, including whether modifying preoperative fasting recommendations or temporarily discontinuing the drug could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Patients are instructed to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). However, the absence of a direct warning about gastroparesis may leave patients and providers unaware of the potential for this condition to develop as a chronic adverse effect.

Statute of Limitations for Ozempic Claims in Georgia

Settlement-related considerations for affected patients in Georgia involve the statute of limitations, which is the time limit within which a lawsuit must be filed. In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For claims involving wrongful death, the limit is also two years from the date of death. Given that gastroparesis symptoms may develop gradually and be initially attributed to other causes, the discovery rule is critical. The timeline between exposure to Ozempic and documented harm is variable; symptoms may emerge during dose escalation or after prolonged use. Patients who experience persistent nausea, vomiting, or abdominal pain while on Ozempic should seek medical evaluation to determine if gastroparesis is present. If diagnosed, the clock for the statute of limitations may start from the date of diagnosis or from when the patient reasonably should have connected the symptoms to Ozempic use. For patients considering legal action, documentation of the timeline is essential. This includes records of when Ozempic was prescribed, when symptoms began, when a gastroparesis diagnosis was made, and any communications with healthcare providers about potential adverse effects. Settlement negotiations may consider the strength of evidence linking Ozempic to gastroparesis, the adequacy of warnings, and the severity of harm. Given the clinical trial data showing elevated rates of gastrointestinal adverse reactions and the postmarketing reports of retained gastric contents, there is a plausible basis for claims. However, each case will depend on individual circumstances, including the presence of other risk factors for gastroparesis, such as diabetes itself, which can also cause gastroparesis. In summary, patients in Georgia who have developed gastroparesis after using Ozempic should be aware of the two-year statute of limitations from the date of discovery of the injury. They should consult with a legal professional experienced in pharmaceutical litigation to evaluate their case and ensure timely filing. The evidence from clinical trials and postmarketing reports supports a mechanistic link between Ozempic and delayed gastric emptying, but the adequacy of warnings remains a contested issue.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Georgia?

In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the limit is also two years from the date of death. Given that gastroparesis symptoms may develop gradually, the discovery rule is critical, and the clock may start from the date of diagnosis or when the patient reasonably should have connected symptoms to Ozempic use.

What evidence links Ozempic to gastroparesis?

Clinical trial data show that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo, including nausea, vomiting, diarrhea, abdominal pain, and constipation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Mechanistically, Ozempic slows gastric emptying via GLP-1 receptor activation, which can become pathological. Postmarketing reports also note rare pulmonary aspiration due to retained gastric contents in patients undergoing surgery (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.